

Robust Clinical Trial Data

LARGEST, MOST COMPREHENSIVE TRIAL PROGRAM IN DRY EYE DISEASE IN SUPPORT OF AN INVESTIGATIONAL PRODUCT

5 clinical trials; more than **2,500** patients¹⁻⁶

PHASE 2 - Efficacy/safety of three concentrations (0.1%, 1.0%, 5.0%)^{1,2}

230
patients

5
sites

12
week trial

Primary endpoint:
Effect on ocular signs

OPUS-1 - Phase 3 efficacy/safety trial^{2,3}

588
patients

13
sites

12
week trial

Primary endpoints:
Effect on ocular signs and symptoms

OPUS-2 - Phase 3 efficacy/safety trial^{2,4}

718
patients

30
sites

12
week trial

Primary endpoints:
Effect on ocular signs and symptoms

OPUS-3 - Phase 3 efficacy/safety trial^{2,5}

711
patients

41
sites

12
week trial

Primary endpoint:
Effect on ocular symptoms

SONATA - Phase 3 safety trial^{2,6}

331
patients

22
sites


1
year trial

Primary endpoint:
Adverse events

COMMITTED TO DRY EYE INNOVATION



~10 years from compound to U.S. FDA approval⁷



1st and only Rx treatment for dry eye signs and symptoms



1st U.S. FDA-approved Tx in more than a decade

INDICATION

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

IMPORTANT SAFETY INFORMATION

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increase lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

For additional safety information, [click here](#) for Full Prescribing Information.